Question · asked by 1 review

Dornase alfa vs alternate days: Pulmonary exacerbations

Population
children with cystic fibrosis
Intervention
Dornase alfa
Comparison
alternate days
Outcome
Pulmonary exacerbations

What each review found

Current versions only
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%
FindingEffectStudiesGRADE certainty
Dornase alfa daily vs alternate days
Number of pulmonary exacerbations at 3 months · Children with cystic fibrosis
Dornase alfa for cystic fibrosis (2021) · Cochrane Headline outcomes only
no estimate extracted43 participantsLow
Dornase alfa daily vs alternate days
Number of pulmonary exacerbations at 3 months · Children with cystic fibrosis
Dornase alfa for cystic fibrosis (2018) · Cochrane Headline outcomes onlyearlier version CD001127.PUB4, superseded
no estimate extracted43 participantsLow
Dornase alfa daily vs alternate days
Number of pulmonary exacerbations at 3 months · Children with cystic fibrosis
Dornase alfa for cystic fibrosis (2016) · Cochrane Headline outcomes onlyearlier version CD001127.PUB3, superseded
no estimate extracted43 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Dornase alfa for cystic fibrosis
2021 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.